ConductScience.org, home

Paper36958590

Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents.

Fizazi K and 2 others. Ann Oncol, 2023. Cited by 106 papers, by iCite.

Cite this record

ConductScience Library. Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents. Papers, record 36958590. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36958590

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents.
PubMed
Journal
Ann Oncol
PubMed
Year
2023
PubMed
Publication types
Practice Guideline, Journal Article
PubMed
Citations, by iCite
106
iCite
Relative citation ratio, by iCite
9.9
iCite
Revised in PubMed
2023-11-19
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fizazi KK
2Gillessen SS
3ESMO Guidelines Committee. Electronic address: [email removed]Group

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Prostatic NeoplasmsMajor topic
Prostatic Neoplasms, Castration-ResistantMajor topic
Male
Humans
Treatment Outcome
Prostate-Specific Antigen

Cited by60

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 106 citations.

PMIDTitleJournalYearIn PapersSource
42757692Real-world treatment patterns in men with metastatic hormone-sensitive prostate cancer in Europe and Asia between 2020 and 2024.Oncologist2026https://conductscience.org/library/papers/42757692PubMed
42588618Real-World Outcomes of DNA Damage Repair Altered Metastatic Castration-Resistant Prostate Cancer: Insights from FFPE-Based Genomic Profiling.Cancers (Basel)2026https://conductscience.org/library/papers/42588618PubMed
42528594Genomic Determinants of Lethality and Therapeutic Vulnerability in Castration-Resistant Prostate Cancer.bioRxiv2026https://conductscience.org/library/papers/42528594PubMed
42449638PSMA PET in Lymph Node Staging of Prostate Cancer: From Diagnostic Accuracy to Clinical Decision-Making.Cancers (Basel)2026https://conductscience.org/library/papers/42449638PubMed
42313080Liver Background Uptake of Prostate-specific Membrane Antigen-targeted PET Radiotracers: A Systematic Review and Meta-Analysis.Radiol Imaging Cancer2026https://conductscience.org/library/papers/42313080PubMed
42279286Circulating Tumor DNA as Emerging Predictive and Prognostic Biomarker in Prostate Cancer.Cancers (Basel)2026https://conductscience.org/library/papers/42279286PubMed
42249939Real-world outcomes of [177Lu]Lu-PSMA-I&T in [18F]FDG-positive metastatic castration-resistant prostate cancer: factors related to response and survival.Eur J Nucl Med Mol Imaging2026https://conductscience.org/library/papers/42249939PubMed
42176182Therapy Optimization in mHSPC: Insights from a Multidisciplinary Uro-Oncology Expert Panel.Adv Ther2026https://conductscience.org/library/papers/42176182PubMed
41979035Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01.Future Oncol2026https://conductscience.org/library/papers/41979035PubMed
41817839Stated Preferences for Systemic Treatments for Prostate Cancer: A Targeted Review of the Discrete-Choice Experiment Literature.Patient2026https://conductscience.org/library/papers/41817839PubMed
41749948Malignancy of Urinary Tract in Kidney Transplant Recipients-A Narrative Review.Cancers (Basel)2026https://conductscience.org/library/papers/41749948PubMed
41667886Treatment patterns in patients with castration-resistant prostate cancer who received darolutamide in the ARAMIS trial in Spain: PARASEC study.Clin Transl Oncol2026https://conductscience.org/library/papers/41667886PubMed
41655999Feasibility and workflow analysis of confocal microscopy in robot-assisted prostatectomy.BJU Int2026https://conductscience.org/library/papers/41655999PubMed
41573730Editorial: Novel therapeutics for urological cancers.Front Pharmacol2025https://conductscience.org/library/papers/41573730PubMed
41450200Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS.Cancer Med2026https://conductscience.org/library/papers/41450200PubMed
41438100Pre-PROTO-PRIME: stereotactic body proton therapy to the prostate and pelvic nodes for high-risk and node-positive prostate cancer - feasibility, acute toxicity and dosimetric insights.Clin Transl Radiat Oncol2026https://conductscience.org/library/papers/41438100PubMed
41385769[Immunotherapy for urological cancers in 2025].Magy Onkol2025https://conductscience.org/library/papers/41385769PubMed
41097735Therapeutic Alliances for Optimizing the Management of Patients with Prostate Cancer: SOGUG Multidisciplinary Expert Panel Recommendations.Cancers (Basel)2025https://conductscience.org/library/papers/41097735PubMed
41097690Real-Life Use Patterns of Androgen Receptor Pathway Inhibitors (ARPIs): A Nationwide Register-Based Study in Finland During 2012-2023.Cancers (Basel)2025https://conductscience.org/library/papers/41097690PubMed
41059299A network meta-analysis of the safety of systemic treatments in patients with metastatic hormone-sensitive prostate cancer.Front Oncol2025https://conductscience.org/library/papers/41059299PubMed

See all 60 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36958590

GET https://conductscience.org/api/papers/v1/36958590/cited_by?page=2